

Rare Mononeuropathies

Wolfgang Löscher

Department of Neurology Medical University Innsbruck wolfgang.loescher@i-med.ac.at



Disclosure

Consultant Fees: Amicus Therapeutics, Sanofi-Genzyme, Biogen, Roche,

Alnylam, Argenx, Alexion, Pfizer, Janssen, UCB

•

• **Speaker Honoraria:** Amicus Therapeutics, Biogen, Roche, CSL, Kedrion, Takeda,

Novartis, Sanofi-Genzyme, Pfizer, Alnylam, Argenx, Alexion

• Industry sponsored studies Alexion, Argenx

• Research Grants: Pfizer

Learing objective

To learn the proper techniques to reach a correct clinical diagnosis.

Increase knowledge of possible and rare etiologies.

Learn to chose the proper tests for diagnostic assessment.

Learn about treatment options and prognosis of rare mononeuropathies.

Key message

A good clinical examination is the key to localize a mononeuropathy.

Several mononeuropathies have been erroneously attributed to nerve compression.

Several mononeuropathies are cause by autoimmune mechanisms.

Some inflammatory mononeuropathies can be treated surgically.